Form 4: Bristol Myers Squibb Director Boosts Equity Holdings

Bristol Myers Squibb Director Michael R. McMullen acquired 648.869 Deferred Share Units, increasing his beneficial ownership to 10,860.897 units.

Summary

• Michael R. McMullen, a Director at Bristol Myers Squibb Company (BMY), acquired 648.869 Deferred Share Units (DSUs).
• The transaction date for this acquisition was December 31, 2025.
• Following this transaction, McMullen beneficially owns a total of 10,860.897 Deferred Share Units.
• Each Deferred Share Unit will convert into one share of common stock upon settlement.
• Settlement of the DSUs occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
• The reported price for the acquisition of these derivative securities was $0, indicating they were likely granted as compensation.
• The total beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The acquisition of additional deferred share units by a director is generally viewed as a positive signal, indicating continued confidence in the company's long-term prospects and aligning management's interests with shareholders. While routine, it adds to the positive sentiment.

Positives

• A director acquiring additional equity, even in the form of deferred share units, can signal confidence in the company's future performance and long-term strategy.
• The increase in beneficial ownership aligns the director's interests more closely with those of shareholders.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction.

Industry Context

This is a routine insider transaction, common across all industries, where a director receives or acquires equity as part of their compensation or through a deferred compensation plan. It does not provide specific insights into broader industry trends or competitive landscape beyond the individual's increased stake in the company.

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a positive indicator of management's commitment and belief in the company's future value.

Next Steps

• The Deferred Share Units will be converted into shares of common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person.

Key Dates

Keywords

Bristol Myers Squibb, BMY, Form 4, Insider Transaction, Director, Deferred Share Units, Equity Acquisition, Beneficial Ownership